Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation

Inclusion Criteria: * Signed informed consent must be obtained prior to participation in the study. * Male or female participants ≥18 years of age at the screening visit with a confirmed diagnosis of Ph+ CML-CP. Participants must meet all of the following laboratory values as confirmed by the available reports of the peripheral blood test or bone marrow examination (performed within 12 months before the screening) at the screening visit to meet the criteria of Ph+ CML-CP: * \<15% blasts in peripheral blood and/or bone marrow * \<30% blasts plus promyelocytes in peripheral blood and/or bone marrow * \<20% basophils in the peripheral blood * ≥50 x 109/L (≥50,000/mm3) platelets# * No evidence of extramedullary leukemic involvement, apart from hepatosplenomegaly. #Transient prior therapy related thrombocytopenia (\<50,000/mm3 for ≤30 days prior to screening) is acceptable. \- a. For Ph+ CML-CP participants with T315I mutation, mutational analysis testing at any time point showing a documented T315I mutation. b. For Ph+ CML-CP participants without T315I mutation, at least 2 prior ATP-site TKIs (i.e., imatinib, nilotinib, bosutinib, dasatinib, or ponatinib) with failure\* (adapted from the 2020 European LeukemiaNet \[ELN\] Recommendations) or intolerance\*\* to the most recent TKI therapy at the time of screening. \*Failure for Ph+ CML-CP participants (CP at the time of initiation of last therapy) is defined as meeting at least one of the following criteria: * Three …